Skip to content
Clinical Trials – home
LithuaniaBack to Lithuania

Clinical trials in Seskine – page 10

191 clinical trials in Seskine, Lithuania. Every trial is listed in the EU Clinical Trials Register and updated daily.

LithuaniaOur site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)
Seskine at a glance
191
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Seskine

Open in trial search

Acromegaly

Not recruiting

Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2420
  • Sponsor:Alexion Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Contraception

Not recruiting

Study on the Effectiveness and Safety of Levonorgestrel Vaginal Delivery System for Preventing Pregnancy in Women

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Levonorgestrel
  • Sponsor:Chemo Research S.L.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Crohn's disease

Not recruiting

Study on Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Celltrion Inc.

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:Debiopharm International S.A.

Lupus nephritis

Not recruiting

Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Other cities in Lithuania

The busiest research cities in the country

All 10 cities in Lithuania
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.